What is Retatrutide? A Breakdown of the Triple-Receptor Peptide

Compound Spotlight

Retatrutide (development code LY3437943) is the most-watched molecule in metabolic research right now, and also one of the most misunderstood. It is routinely described as “the next GLP-1,” which undersells what is actually novel about it. This article covers the molecular design, what each of its three receptor targets contributes, what the published trial data actually shows, and where the genuine open questions remain.

The molecule itself

Retatrutide is a synthetic 39-amino-acid peptide built on a GIP-analog backbone, with a fatty-acid side chain attached to enable albumin binding. That last detail is what makes once-weekly administration possible in trials: binding to serum albumin protects the peptide from rapid renal clearance and enzymatic breakdown, extending its half-life to roughly six days. Without that modification, a peptide this size would be cleared in hours.

The design lineage matters for understanding it. GIP, GLP-1, and glucagon all belong to the same structural family of peptide hormones and share a common ancestral sequence. That shared architecture is precisely what makes a single molecule capable of engaging all three receptors — the engineering problem was not inventing a hybrid from scratch, but tuning the relative potency at each receptor so that one activity does not overwhelm the others.

What each receptor contributes

GLP-1 receptor

The most familiar of the three. GLP-1 receptor activation slows gastric emptying, enhances glucose-dependent insulin secretion, suppresses glucagon release after meals, and acts on hypothalamic circuits that regulate appetite. This is the mechanism behind the entire semaglutide generation of compounds. It is also the primary source of the nausea and gastrointestinal effects seen across this whole drug class.

GIP receptor

GIP is the other major incretin hormone. Its role is less intuitive and remains genuinely contested in the literature — there is an unresolved debate about whether GIP receptor agonism or antagonism is the more useful strategy, with credible compounds in development on both sides. In the agonist case, GIP is studied for effects on insulin secretion, adipose tissue nutrient handling, and, notably, for anti-emetic effects in the brainstem that may partially offset GLP-1-driven nausea, potentially allowing higher effective dosing than GLP-1 alone would tolerate.

Glucagon receptor

This is the one that makes retatrutide structurally distinct from tirzepatide and everything before it. Glucagon is best known as insulin’s counter-regulatory partner: it raises blood glucose by driving hepatic glucose output. Deliberately activating that receptor in a metabolic compound sounds backwards.

The rationale is that glucagon also increases resting energy expenditure and stimulates hepatic fat oxidation. In other words, GLP-1 and GIP largely reduce energy intake, while glucagon increases energy output — a fundamentally different lever. The hyperglycemic risk is managed by the fact that the co-administered GLP-1 and GIP activity is insulinotropic, counterbalancing glucagon’s effect on blood sugar. Getting that balance right is the central pharmacological achievement of the molecule, and it is why relative receptor potency ratios matter more here than raw potency.

What the trial data actually shows

The Phase 2 trial (Jastreboff et al., New England Journal of Medicine, 2023, NCT04881760) enrolled 338 adults with obesity, or overweight with a weight-related condition, and no type 2 diabetes. At 48 weeks, least-squares mean body-weight change was −8.7% at 1 mg, −17.1% at 4 mg, −22.8% at 8 mg, and −24.2% at 12 mg, against −2.1% for placebo. Among participants on 12 mg, 83% reached at least 15% weight reduction. Those figures were the highest reported for a non-surgical intervention at the time of publication.

Phase 3 results have since begun reporting. TRIUMPH-4, in adults with obesity and knee osteoarthritis, reported 28.7% mean weight reduction at 68 weeks on 12 mg in December 2025, alongside improvements in osteoarthritis pain scores. TRIUMPH-1, the pivotal general-obesity trial, met its primary endpoint in May 2026. Additional readouts across type 2 diabetes, cardiovascular outcomes, sleep apnea, and liver disease are expected to continue reporting through 2026 and beyond.

The liver-fat signal

One of the more scientifically interesting findings sits in a Phase 2a substudy of participants with metabolic dysfunction-associated steatotic liver disease. At 24 weeks, mean relative liver-fat reduction was −81.4% at 8 mg and −82.4% at 12 mg, with 86% of the 12 mg group reaching normal liver fat (under 5%). Reductions of that magnitude are difficult to explain by weight loss alone, and are consistent with glucagon receptor activity acting directly on hepatic fat oxidation. If that interpretation holds, it would be a mechanistic advantage specific to triple agonism rather than a general property of the drug class.

Tolerability and open questions

The adverse-event profile is dominated by gastrointestinal effects — nausea, vomiting, diarrhea, constipation — which is expected for this class and is dose-dependent. Reported rates have run higher than previously seen with GLP-1 and GLP-1/GIP compounds, and trial discontinuation due to adverse events increased with dose. Dose-dependent heart-rate increases have also been observed, a recognized effect across incretin-based compounds that remains under evaluation in longer cardiovascular trials.

Several questions remain genuinely unresolved. Long-term cardiovascular outcome data is not yet in. The durability of weight reduction after discontinuation has not been characterized for this molecule. The composition of weight lost — the proportion of lean mass versus fat mass — is an active concern across the entire class. And because glucagon receptor agonism is new to this category, the long-term hepatic and glycemic consequences of sustained activation are not yet backed by multi-year data.

How it compares to related compounds

Semaglutide is a single-receptor GLP-1 agonist. Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds the third receptor. Trial results across these compounds show progressively greater weight reduction as receptors are added, but it is worth being careful here: these are separate trials with different populations, durations, and designs, not head-to-head comparisons. Cross-trial comparison is suggestive, not conclusive, and the field generally treats it that way.

Regulatory status

Retatrutide is investigational. It is not approved by the FDA, the EMA, or any other regulator, for any indication, anywhere. There is no approved prescription pathway. Everything known about it in humans comes from the sponsor-funded clinical trial program described above, conducted under medical supervision with defined protocols and monitoring.

Handling and stability

As a lyophilized peptide, retatrutide is subject to the same degradation chemistry as any other compound in this category: hydrolysis once reconstituted, oxidation accelerated by light exposure, and structural denaturation from heat or repeated freeze-thaw cycling. The albumin-binding fatty-acid chain affects its pharmacokinetics in circulation, not its stability in a vial. Standard cold, dark, single-thaw handling applies.

Frequently asked questions

Why include glucagon when it raises blood sugar?

Because glucagon also raises energy expenditure and drives hepatic fat oxidation. The insulinotropic activity of the GLP-1 and GIP components is what offsets the glycemic effect. The balance between the three activities is the point of the molecule, not an incidental detail.

Is retatrutide just a stronger version of tirzepatide?

No. It engages a different receptor set. Tirzepatide’s two receptors both act primarily on intake and insulin signaling; retatrutide’s third receptor introduces an energy-expenditure and hepatic mechanism that the dual agonists do not have.

Why does the trial data cite specific milligram figures?

Those are the dose arms studied in registered clinical trials under medical supervision, reported here as published research findings. They describe what was tested in a controlled setting, not a protocol for any other context.

How do I know what is actually in the vial?

Every lot we sell has a published Certificate of Analysis from an independent, third-party lab confirming identity by mass spectrometry and purity by HPLC. Lot numbers on the vial should match the COA you are referencing.

References

• Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526.
• Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024.
• Rosenstock J, et al. Retatrutide in people with type 2 diabetes: a randomised, phase 2 trial. The Lancet. 2023.
• Eli Lilly and Company. TRIUMPH-4 and TRIUMPH-1 topline results announcements, 2025–2026.

View the Retatrutide product listing →

Read our guide to GLP-1 research peptides →

Look up your lot Certificate of Analysis →

For laboratory and research use only. Not for human consumption. Retatrutide is an investigational compound not approved by any regulatory authority. This article summarizes published research for informational purposes and is not medical advice, nor a recommendation or protocol for use.

Related research compounds

Arc Peptides supplies these compounds, each third-party tested for purity and identity with a lot-specific Certificate of Analysis:

• Retatrutide

For laboratory research use only. Not for human consumption.